These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 22895559)

  • 1. Assessing personalized medicines in Australia: a national framework for reviewing codependent technologies.
    Merlin T; Farah C; Schubert C; Mitchell A; Hiller JE; Ryan P
    Med Decis Making; 2013 Apr; 33(3):333-42. PubMed ID: 22895559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group.
    Faulkner E; Annemans L; Garrison L; Helfand M; Holtorf AP; Hornberger J; Hughes D; Li T; Malone D; Payne K; Siebert U; Towse A; Veenstra D; Watkins J;
    Value Health; 2012 Dec; 15(8):1162-71. PubMed ID: 23244820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value assessment of antimicrobials and the implications for development, access, and funding of effective treatments: Australian stakeholder perspective.
    Hillock NT; Merlin TL; Karnon J; Turnidge J; Eliott J
    Int J Technol Assess Health Care; 2020 Nov; 37():e28. PubMed ID: 33138869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inaugural Pharmacogenomics Access and Reimbursement Symposium.
    Rogers SL; Patrinos GP; Mitropoulou C; Formea CM; Jones JS; Brown BG
    Pharmacogenomics; 2021 Jun; 22(9):515-517. PubMed ID: 34032472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARC report: health outcomes and value of personalized medicine interventions: impact on patient care.
    Mitropoulou C; Litinski V; Kabakchiev B; Rogers S; P Patrinos G
    Pharmacogenomics; 2020 Jul; 21(11):797-807. PubMed ID: 32635813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ENVIRONMENTAL SCAN ON PHARMACEUTICALS REQUIRING COMPANION DIAGNOSTICS.
    Cowling T; Boucher M
    Int J Technol Assess Health Care; 2016 Jan; 32(5):327-336. PubMed ID: 27955717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Health technology assessment and its impact on pharmaceutical pricing and reimbursement policies].
    Castillo-Laborde C; Silva-Illanes N
    Rev Med Chil; 2014 Jan; 142 Suppl 1():S33-8. PubMed ID: 24861178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health technology assessment in Australia: a role for clinical registries?
    Scott AM
    Aust Health Rev; 2017 Mar; 41(1):19-25. PubMed ID: 27028134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncotyrol--Center for Personalized Cancer Medicine: Methods and Applications of Health Technology Assessment and Outcomes Research.
    Siebert U; Jahn B; Rochau U; Schnell-Inderst P; Kisser A; Hunger T; Sroczynski G; Mühlberger N; Willenbacher W; Schnaiter S; Endel G; Huber L; Gastl G;
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):330-40. PubMed ID: 26354133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health Technology Assessment in Australia: The Pharmaceutical Benefits Advisory Committee and Medical Services Advisory Committee.
    Kim H; Byrnes J; Goodall S;
    Value Health Reg Issues; 2021 May; 24():6-11. PubMed ID: 33429153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decision Making on Medical Innovations in a Changing Health Care Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies.
    Trosman JR; Weldon CB; Douglas MP; Deverka PA; Watkins JB; Phillips KA
    Value Health; 2017 Jan; 20(1):40-46. PubMed ID: 28212967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early cost-effectiveness modeling for better decisions in public research investment of personalized medicine technologies.
    Ling DI; Lynd LD; Harrison M; Anis AH; Bansback N
    J Comp Eff Res; 2019 Jan; 8(1):7-19. PubMed ID: 30525982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health technology assessment. The pharmaceutical industry perspective.
    Schubert F
    Int J Technol Assess Health Care; 2002; 18(2):184-91. PubMed ID: 12053418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
    Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
    Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons learned from the reimbursement policy for immune checkpoint inhibitors and real-world data collection in Taiwan.
    Huang LY; Gau CS
    Int J Technol Assess Health Care; 2020 Dec; 37():e26. PubMed ID: 33342447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re-focusing the ethical discourse on personalized medicine: a qualitative interview study with stakeholders in the German healthcare system.
    Schleidgen S; Marckmann G
    BMC Med Ethics; 2013 May; 14():20. PubMed ID: 23705623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are cancer drugs less likely to be recommended for listing by the Pharmaceutical Benefits Advisory Committee in Australia?
    Chim L; Kelly PJ; Salkeld G; Stockler MR
    Pharmacoeconomics; 2010; 28(6):463-75. PubMed ID: 20465315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shedding Light on Reimbursement Policies of Companion Diagnostics in European Countries.
    Govaerts L; Simoens S; Van Dyck W; Huys I
    Value Health; 2020 May; 23(5):606-615. PubMed ID: 32389226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.